SLC2A1 and cancer: Metabolites which specifically modify the activity of certain GLUT isoforms would therefore be very valuable for cancer therapy which is furthermore encouraged by studies showing that cancer cells die faster than normal cells under glucose-limiting conditions (Liu et al., 2010).